Extrafine inhaled corticosteroid therapy in the control of asthma

István Ivancsó, Renáta Böcskei, V. Müller, L. Tamási

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Small airways disease plays an important role in the pathogenesis of asthma, but assessment of small airways impairment is not easy in everyday clinical practice. The small airways can be examined by several invasive and noninvasive methods, most of which can at present be used only in the experimental setting. Inhalers providing extrafine inhaled corticosteroid particle sizes may achieve sufficient deposition in the peripheral airways. Many studies have reported the beneficial effects of extrafine inhaled corticosteroids on inflammation, ie, on dysfunction in both the central and distal airways in asthmatics, and there are some data on asthma phenotypes in which the small airways seem to be affected more than in other phenotypes, including nocturnal asthma, severe steroid-dependent or difficult-to-treat asthma, asthma complicated by smoking, elderly asthmatic patients and/or patients with fixed airflow obstruction, and asthmatic children. The relevant randomized controlled clinical trials indicate that the efficacy of extrafine and nonextrafine inhaled corticosteroid formulations is similar in terms of primary endpoints, but there are certain clinically important endpoints for which the extrafine formulations show additional benefits.

Original languageEnglish
Pages (from-to)69-80
Number of pages12
JournalJournal of Asthma and Allergy
Issue number6
DOIs
Publication statusPublished - 2013

Fingerprint

Adrenal Cortex Hormones
Asthma
Phenotype
Therapeutics
Nebulizers and Vaporizers
Particle Size
Randomized Controlled Trials
Smoking
Steroids
Inflammation

Keywords

  • Dysfunction
  • Inflammation
  • Noninvasive evaluation methods
  • Peripheral deposition
  • Small airways

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

Extrafine inhaled corticosteroid therapy in the control of asthma. / Ivancsó, István; Böcskei, Renáta; Müller, V.; Tamási, L.

In: Journal of Asthma and Allergy, No. 6, 2013, p. 69-80.

Research output: Contribution to journalArticle

@article{1baedc814d2549e09e6f801b35f7f6d5,
title = "Extrafine inhaled corticosteroid therapy in the control of asthma",
abstract = "Small airways disease plays an important role in the pathogenesis of asthma, but assessment of small airways impairment is not easy in everyday clinical practice. The small airways can be examined by several invasive and noninvasive methods, most of which can at present be used only in the experimental setting. Inhalers providing extrafine inhaled corticosteroid particle sizes may achieve sufficient deposition in the peripheral airways. Many studies have reported the beneficial effects of extrafine inhaled corticosteroids on inflammation, ie, on dysfunction in both the central and distal airways in asthmatics, and there are some data on asthma phenotypes in which the small airways seem to be affected more than in other phenotypes, including nocturnal asthma, severe steroid-dependent or difficult-to-treat asthma, asthma complicated by smoking, elderly asthmatic patients and/or patients with fixed airflow obstruction, and asthmatic children. The relevant randomized controlled clinical trials indicate that the efficacy of extrafine and nonextrafine inhaled corticosteroid formulations is similar in terms of primary endpoints, but there are certain clinically important endpoints for which the extrafine formulations show additional benefits.",
keywords = "Dysfunction, Inflammation, Noninvasive evaluation methods, Peripheral deposition, Small airways",
author = "Istv{\'a}n Ivancs{\'o} and Ren{\'a}ta B{\"o}cskei and V. M{\"u}ller and L. Tam{\'a}si",
year = "2013",
doi = "10.2147/JAA.S25415",
language = "English",
pages = "69--80",
journal = "Journal of Asthma and Allergy",
issn = "1178-6965",
publisher = "Dove Medical Press Ltd.",
number = "6",

}

TY - JOUR

T1 - Extrafine inhaled corticosteroid therapy in the control of asthma

AU - Ivancsó, István

AU - Böcskei, Renáta

AU - Müller, V.

AU - Tamási, L.

PY - 2013

Y1 - 2013

N2 - Small airways disease plays an important role in the pathogenesis of asthma, but assessment of small airways impairment is not easy in everyday clinical practice. The small airways can be examined by several invasive and noninvasive methods, most of which can at present be used only in the experimental setting. Inhalers providing extrafine inhaled corticosteroid particle sizes may achieve sufficient deposition in the peripheral airways. Many studies have reported the beneficial effects of extrafine inhaled corticosteroids on inflammation, ie, on dysfunction in both the central and distal airways in asthmatics, and there are some data on asthma phenotypes in which the small airways seem to be affected more than in other phenotypes, including nocturnal asthma, severe steroid-dependent or difficult-to-treat asthma, asthma complicated by smoking, elderly asthmatic patients and/or patients with fixed airflow obstruction, and asthmatic children. The relevant randomized controlled clinical trials indicate that the efficacy of extrafine and nonextrafine inhaled corticosteroid formulations is similar in terms of primary endpoints, but there are certain clinically important endpoints for which the extrafine formulations show additional benefits.

AB - Small airways disease plays an important role in the pathogenesis of asthma, but assessment of small airways impairment is not easy in everyday clinical practice. The small airways can be examined by several invasive and noninvasive methods, most of which can at present be used only in the experimental setting. Inhalers providing extrafine inhaled corticosteroid particle sizes may achieve sufficient deposition in the peripheral airways. Many studies have reported the beneficial effects of extrafine inhaled corticosteroids on inflammation, ie, on dysfunction in both the central and distal airways in asthmatics, and there are some data on asthma phenotypes in which the small airways seem to be affected more than in other phenotypes, including nocturnal asthma, severe steroid-dependent or difficult-to-treat asthma, asthma complicated by smoking, elderly asthmatic patients and/or patients with fixed airflow obstruction, and asthmatic children. The relevant randomized controlled clinical trials indicate that the efficacy of extrafine and nonextrafine inhaled corticosteroid formulations is similar in terms of primary endpoints, but there are certain clinically important endpoints for which the extrafine formulations show additional benefits.

KW - Dysfunction

KW - Inflammation

KW - Noninvasive evaluation methods

KW - Peripheral deposition

KW - Small airways

UR - http://www.scopus.com/inward/record.url?scp=84879006385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879006385&partnerID=8YFLogxK

U2 - 10.2147/JAA.S25415

DO - 10.2147/JAA.S25415

M3 - Article

C2 - 23776339

AN - SCOPUS:84879006385

SP - 69

EP - 80

JO - Journal of Asthma and Allergy

JF - Journal of Asthma and Allergy

SN - 1178-6965

IS - 6

ER -